NCT06244979View on ClinicalTrials.gov

iMagIng pulmonaRy Aspergillosis Using Gallium-68-dEferoxamine

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2026

Conditions
Pulmonary AspergillosisChronic Pulmonary AspergillosisAllergic Bronchopulmonary Aspergillosis
Interventions
OTHER

Radiopharmaceutical: gallium-68-deferoxamine ([68Ga]Ga-DFO-B)

100 MBq +/- 10% \[68Ga\]Ga-DFO-B which contains 100 µg DFO-B (see description in arm description)

Trial Locations (1)

Unknown

RECRUITING

RadboudUMC, Nijmegen

All Listed Sponsors
lead

Radboud University Medical Center

OTHER